演題抄録

FACO Symposium

開催概要
開催回
第51回・2013年・京都
 

Targeted therapy for gastric cancer in different population

演題番号 : FS-2

[筆頭演者]
Jin Li:1 

1:Fudan University Cancer Center, China

 

Targeted cancer therapies provide new hope to patients with gastric cancer. For the Her-2 positive mGC patients, trastuzumab could provide higher efficacy. The evidence of anti-VEGF/VEGFR activity leading to improved OS or progression-free survival (PFS) in patients with mGC is limited although subgroup analysis of data from the phase III Avastin in Gastric Cancer (AVAGAST) trial showed that the VEGF inhibitor bevacizumab tended to improve OS in non-Asian patients with high versus low levels of plasma VEGF-A, indicating that the compound might have some benefit for selected patients. The trials with TK inhibitors of mTOR and Her-2 frustrated us. Recently, more optimistic results were reported from a randomized, placebo-controlled study with ramucirumab. In this phase III study, patients with mGC treated with ramucirumab had longer PFS and OS than patients given placebo. The anti-VEGFR TKI, Apatinib showed same promising results recently when applied to second or more line chemo refractory patients. These agents will be a new choice for the patients who failed to chemotherapy and should provide longer survival time.

前へ戻る